UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 24, 2020
JUPITER WELLNESS, INC.
(Exact name of registrant as specified in charter)
| Delaware | 001-39569 | 83-2455880 | ||
| (State or other jurisdiction | (Commission | (IRS Employer | ||
| of incorporation) | File Number) | Identification No.) |
725 N. Hwy A1A, Suite C-106 Jupiter, FL 33477
(Address of principal executive offices) (Zip Code)
(561) 244-7100
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| [ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| Common Stock | JUPW |
The Nasdaq Stock Market LLC (The Nasdaq Capital Market)
| ||
| Warrants, each exercisable for one share of Common Stock at $8.50 per share | JUPWW |
The Nasdaq Stock Market LLC (The Nasdaq Capital Market) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company [X]
If an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item 7.01 Regulation FD Disclosure
On November 24, 2020 Jupiter Wellness, Inc. issued the attached press release. A copy of the press release is attached hereto and incorporated herein by reference in its entirety as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits
Exhibits
| Exhibit No. | Description | |
| 99.1 | Press release, dated November 24, 2020 |
| 1 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 24, 2020
| JUPITER WELLNESS, INC. | ||
| By: | /s/ Brian John | |
| Brian John | ||
| Chief Executive Officer | ||
| 2 |
Jupiter Wellness Initiates Clinical Study of CaniSun for the Treatment of Actinic Keratosis.
| · | 58 million Americans have Actinic Keratosis (AK) the most common precancer of the skin. |
| · | The study to investigate if CaniSun may act as a prophylactic, reducing the occurrence of actinic keratosis (AK) and potentially inhibiting AK’s progression into squamous cell carcinoma. |
Jupiter, FL – Accesswire - November 24, 2020 - Jupiter Wellness, Inc. (Nasdaq: JUPW), announced today they are initiating a clinical study of its CaniSun™ sunscreen lotion for the treatment of actinic keratosis (AK), the most common precancer that forms on the skin as a result of exposure to ultraviolet (UV) rays. The Skin Cancer Foundation, estimates 58 million Americans have one or more AK lesions which appear as raised, scaly discolored patches on sun exposed skin. Left untreated, approximately 20% of AK lesions progress to squamous cell carcinoma.
The primary objective of this study is to evaluate Canisun as a treatment for Actinic Keratosis by evaluating the efficacy in both treatment and prophylaxis of patients. The clinical study will recruit an estimated 116 adults diagnosed with Actinic Keratosis and will be conducted by Applied Biology (Irvine, CA) The primary efficacy endpoint is the percentage of patients with complete clearance of AK lesions.
CaniSun is an over-the-counter (OTC) product, which in addition to being an effective sunscreen, may act as a prophylactic treatment to prevent AK from occurring and/or to inhibit its progression into squamous cell carcinoma (skin cancer). Current treatment protocol for AK is surgical removal and/or medication. Treatments on the market include the prescription cream Imiquimod, an immune response modifier; however, such creams may cause adverse side effects including intense local inflammation. CaniSun’s potential efficacy may position it as an alternative therapy.
“I am excited to work with Applied Biology in the clinical evaluation of Canisun, which may have the potential to offer relief from this side-effect to patients exposure to UV rays" said Brian John CEO of Jupiter Wellness. "Initiating this AK study represents an important opportunity for Jupiter Wellness to obtain patient data and evaluate any potential benefits of our sunscreen products”.
About Jupiter Wellness
Jupiter Wellness, Inc. (NASDAQ: JUPW) is a developer
of cannabidiol (CBD) based medical therapeutics and wellness products. The Company’s clinical pipeline of CBD-enhanced skin
care therapeutics address indications including eczema, burns, herpes cold sores, and skin cancer. Jupiter generates revenues
from a growing line of proprietary over-the-counter skincare products including its CaniSun™ sunscreen and other wellness
brands.
For additional information, please visit www.JupiterWellnessInc.com. The Company’s public filings can be found at www.Sec.gov.
Safe Harbor Statement
To the extent any statements contained in this presentation of Jupiter Wellness, Inc. (the “Company”) contains “forward-looking
statements” as defined in the Private Securities Litigation Reform Act of 1995 and the information that are based upon beliefs
of, and information currently available to, the company’s management as well as estimates and assumptions made by the company’s
management. These statements can be identified by the fact that they do not relate strictly to historic or current facts. When
used in this presentation the words “estimate,” “expect,” intend,” believe,” plan,” “anticipate,”
“projected” and other words or the negative of these terms and similar expressions as they relate to the company or
the company’s management identify forward-looking statements. Such statements reflect the current view of the company with
respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the company’s
industry, its operations and results of operations and any businesses that may be acquired by the company. Should one or more of
these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly
from those anticipated, believed, estimated, expected, intended, or planned. Although the company believes that the expectations
reflected in the forward-looking statements are reasonable, the company cannot guarantee future results, performance, or achievements.
Except as required by applicable law, including the security laws of the United States, the company does not intend to update any
of the forward-looking statements to conform these statements to actual results.
Investor & Public Relations Contact Info
Phone: 561-244-7100
Email: info@JupiterWellnessInc.com